Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Bradley A. McGregor, Guru Sonpavde, Charlene Mantia et al.|Journal of Clinical Oncology|2022

Cited by 7